Clinical Trial Update: Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

View source ↗

Summary

Tipranavir has been approved for marketing for HIV-1 infection in protease inhibitor-experienced patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Tipranavir (tipranavir)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: HIV Infections | Status: APPROVED_FOR_MARKETING